Celgene's (CELG -0.1%) Apremilast drug significantly improved the signs and symptoms of patients...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene's (CELG -0.1%) Apremilast drug significantly improved the signs and symptoms of patients with psoriatic arthritis in the company's "Palace 3" Phase III study. The results come a day after Celgene reported a positive outcome from "Palace I". In total, the company is conducting four Phase III "Palace" trials. (PR)